PubMed

Adolescents at risk for MODY3 diabetes prefer genetic testing before adulthood.

Liljeström B, Tuomi T, Isomaa B, Sarelin L, Aktan-Collan K, Kääriäinen H.

Diabetes Care. 2007 Jun;30(6):1571-3. Epub 2007 Mar 10. No abstract available. PMID: 17351287 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.

Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC.

Diabetes Care. 2006 Feb;29(2):189-94.PMID: 16443858 [PubMed - indexed for MEDLINE]Related articlesFree article

Genetic testing for maturity onset diabetes of the young: uptake, attitudes and comparison with hereditary non-polyposis colorectal cancer.

Liljeström B, Aktan-Collan K, Isomaa B, Sarelin L, Uutela A, Groop L, Kääriäinen H, Tuomi T.

Diabetologia. 2005 Feb;48(2):242-50. Epub 2005 Jan 20.PMID: 15660263 [PubMed - indexed for MEDLINE]Related articles

Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA).

Isomaa B, Almgren P, Henricsson M, Taskinen MR, Tuomi T, Groop L, Sarelin L.

Diabetes Care. 1999 Aug;22(8):1347-53.PMID: 10480781 [PubMed - indexed for MEDLINE]Related articlesFree article

Chronic diabetic complications in patients with MODY3 diabetes.

Isomaa B, Henricsson M, Lehto M, Forsblom C, Karanko S, Sarelin L, Häggblom M, Groop L.

Diabetologia. 1998 Apr;41(4):467-73.PMID: 9562352 [PubMed - indexed for MEDLINE]Related articles

Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect.

Lehto M, Tuomi T, Mahtani MM, Widén E, Forsblom C, Sarelin L, Gullström M, Isomaa B, Lehtovirta M, Hyrkkö A, Kanninen T, Orho M, Manley S, Turner RC, Brettin T, Kirby A, Thomas J, Duyk G, Lander E, Taskinen MR, Groop L.

J Clin Invest. 1997 Feb 15;99(4):582-91.PMID: 9045858 [PubMed - indexed for MEDLINE]Related articlesFree article